Opendata, web and dolomites

IRL790

NOVEL THERAPEUTIC FOR THE TREATMENT OF PARKINSONS DISEASE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IRL790 project word cloud

Explore the words cloud of the IRL790 project. It provides you a very rough idea of what is the project "IRL790" about.

medical    severe    symptomatic    prescribed    successful    platform    complications    candidates    network    cns    lids    superior    people    clinical    burden    captures    rates    data    indications    validating    isp    bodies    innovation    license    validated    neurodegenerative    investors    worldwide    yields    sme    trials    savings    plan    psychosis    relief    million    death    quality    psychotic    irl790    integrative    levodopa    complexities    chance    disorder    providers    reducing    ongoing    business    proprietary    disease    highest    accelerate    healthcare    clinic    diseases    developmental    tolerability    gained    disability    screening    treatment    sooner    motor    safety    national    therapeutic    leads    clinically    simultaneously    market    gt    generation    symptoms    trust    2018    patients    discovery    debilitating    neurological    compound    intervention    efficacy    contact    besides    international    benefits    pd    adjusted    parkinson    prevalence    ago    grant    irlab    licensing    combats    life    dyskinesia    outcomes    drug    dalys   

Project "IRL790" data sheet

The following table provides information about the project.

Coordinator
INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.irlab.se/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB SE (GOTEBORG) coordinator 50˙000.00

Map

 Project objective

This project’s goal is to develop a successful treatment that combats severe motor and psychotic symptoms in Parkinson’s disease (PD). PD is a debilitating neurodegenerative disorder affecting > 6 million people worldwide. It’s the neurological disorder with the highest increase in death rates, prevalence, and disability-adjusted life-years (DALYs). Levodopa, introduced more than 50 years ago, remains the most prescribed treatment for the symptomatic relief of PD, although its long-term use leads to the development of motor complications, i.e. levodopa-induced dyskinesia (PD-LIDs). IRLAB aims to address the challenge in PD treatment by clinically validating its novel compound, IRL790, aimed at reducing symptoms of PD-LIDs and Parkinson’s disease psychosis. IRLAB’s programme is based on its proprietary drug discovery platform, Integrative Screening Process (ISP), which captures a better understanding of complexities of CNS-related diseases, such as PD, and yields drug candidates with superior chance of success in the clinic. IRLAB’s therapeutic will improve intervention outcomes for PD patients in two indications. Its safety and tolerability have been validated in Phase I clinical trials and its therapeutic efficacy in PD-LIDs is being evaluated in an ongoing Phase II study. Results are expected 2018. Besides medical benefits to patients, IRL790 has also the potential to bring cost-savings to healthcare providers by effectively reducing the Parkinson’s disease burden. Generation of high quality clinical data will improve IRLAB’s opportunities for out-licensing. We plan to apply for SME grant to accelerate clinical developmental and take IRL790 through a Phase II study in PD psychosis. This way, we will out-license and market the drug sooner and for two indications (PD-LIDs and PD psychosis) simultaneously. IRLAB has an established business development contact network and have gained trust of international healthcare investors and national innovation funding bodies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRL790" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IRL790" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

ALICE (2019)

Armored Liftable anti-Intrusion Control Equipment

Read More